Predicting response to PD-L1 inhibitor after chemoradiotherapy for limited-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study uses a blood test to see if it can predict how well the PD-L1 inhibitor (an immunotherapy drug) works after standard chemotherapy and radiation for limited-stage small cell lung cancer. It aims to find better ways to match treatment to patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have limited-stage small cell lung cancer (cancer that is only in one lung and nearby lymph nodes).
- You can have had up to 2 cycles of chemotherapy, but no other cancer treatment before.
- You must be in good general health (able to do daily activities with little or no help).
- You need at least one tumor that can be measured on scans (for example, a tumor that is at least 1 cm or a lymph node that is at least 1.5 cm).
- Your blood counts and organ function (kidney, liver) must be within safe limits as checked by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines radiation therapy with chemotherapy and an immunotherapy drug to treat limited-stage small cell lung cancer. The goal is to see if this approach helps people live longer and delays the cancer from coming back.
This trial tests a new combination of an immunotherapy drug, a targeted therapy, and standard chemotherapy plus radiation for people with limited-stage small cell lung cancer. It aims to see if this combination improves outcomes compared to standard treatment alone.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This trial is testing whether adding the immunotherapy drug serplulimab to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. It is for those who have not had any previous treatment for their cancer.
This Phase 2 study tests whether adding a PD-L1 antibody to chemotherapy helps people with newly diagnosed limited-stage small-cell lung cancer live longer and control the cancer better. It may benefit patients who have not had any prior cancer treatment for SCLC and can meet health and lab requirements.
This study is testing a new combination treatment for early-stage small-cell lung cancer. It compares giving immunotherapy drugs (PD-1/PD-L1 inhibitors) along with chemotherapy before surgery versus chemotherapy alone, to see if the combination helps shrink tumors more effectively and improves outcomes.
Hear when a new Limited-stage Small Cell Lung Cancer (LS-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.